Digirad Reports Exclusive Int'l Distribution Deal with Dilon Diagnostics
Digirad Corporation (NASDAQ: DRAD), the leader in solid-state diagnostic imaging technology and services, and Dilon Diagnostics, the world leader in molecular breast imaging, today announced that they have signed an exclusive international distribution agreement for Dilon to distribute Digirad's lines of nuclear imaging cameras including the ergo™, a large field-of-view general purpose imaging system, the Cardius® x.act, a triple-head cardiac dedicated SPECT imaging system with VCT Attenuation Correction, and the Cardius® XPO dedicated cardiac SPECT imaging systems line. The agreement covers distribution of Digirad products to most countries outside the United States. The signing of this agreement furthers the relationship that Digirad and Dilon have been building since the two companies signed a technology development agreement in mid-2010.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.